ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 675,62
-0,26%
Dow Jones
39 375,87
0,17%
DAX
18 475,45
0,12%
Brent Oil
86,775
0,00%
Bitcoin
57 919,81
2,24%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. NanoViricides Inc (NNVC)

  7. NanoViricides Inc (NNVC) Actualités

NNVC

NanoViricides (NNVC)

NanoViricides Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:NNVC
DateHeureSourceTitreSymboleSociété
02/05/202416h07InvestorsHub NewsWireNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected SoonAMEX:NNVCNanoViricides Inc
16/02/202422h53Edgar (US Regulatory)Form 8-K - Current reportAMEX:NNVCNanoViricides Inc
14/02/202422h55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:NNVCNanoViricides Inc
04/12/202322h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:NNVCNanoViricides Inc
13/10/202322h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:NNVCNanoViricides Inc
28/09/202322h44Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405AMEX:NNVCNanoViricides Inc
06/07/202317h16InvestorsHub NewsWireClinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical NeedsAMEX:NNVCNanoViricides Inc
25/05/202322h34Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NNVCNanoViricides Inc
08/05/202323h20Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)AMEX:NNVCNanoViricides Inc
04/05/202312h45GlobeNewswire Inc.NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York CityAMEX:NNVCNanoViricides Inc
14/02/202323h24Edgar (US Regulatory)Quarterly Report (10-q)AMEX:NNVCNanoViricides Inc
23/12/202212h04Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)AMEX:NNVCNanoViricides Inc
15/11/202222h32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:NNVCNanoViricides Inc
04/11/202221h33Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)AMEX:NNVCNanoViricides Inc
13/10/202223h13Edgar (US Regulatory)Annual Report (10-k)AMEX:NNVCNanoViricides Inc
29/09/202218h20Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)AMEX:NNVCNanoViricides Inc
11/08/202200h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:NNVCNanoViricides Inc
15/11/202113h09InvestorsHub NewsWireNanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2AMEX:NNVCNanoViricides Inc
11/10/202112h49InvestorsHub NewsWireNanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus ActivityAMEX:NNVCNanoViricides Inc
05/10/202112h45PR Newswire (US)NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap ConferenceAMEX:NNVCNanoViricides Inc
22/09/202112h48InvestorsHub NewsWireSignificantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral DrugAMEX:NNVCNanoViricides Inc
14/09/202113h02InvestorsHub NewsWireNanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug DevelopmentAMEX:NNVCNanoViricides Inc
09/03/202115h30InvestorsHub NewsWireNanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in ....ContAMEX:NNVCNanoViricides Inc
02/03/202113h00InvestorsHub NewsWireNanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinicalAMEX:NNVCNanoViricides Inc
17/02/202113h00InvestorsHub NewsWireNanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug ....contAMEX:NNVCNanoViricides Inc
16/02/202115h48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)AMEX:NNVCNanoViricides Inc
08/02/202112h36InvestorsHub NewsWireNanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP..C...AMEX:NNVCNanoViricides Inc
27/01/202113h00InvestorsHub NewsWireBroad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus VariantsAMEX:NNVCNanoViricides Inc
03/12/202022h31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)AMEX:NNVCNanoViricides Inc
19/11/202012h47InvestorsHub NewsWireNanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPAAMEX:NNVCNanoViricides Inc
 Showing the most relevant articles for your search:AMEX:NNVC

Dernières Valeurs Consultées

EU
CAP
Capgemini
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
EU
GLE
Societe Generale
EU
AF
Air FranceKLM
EU
ACA
Credit Agricole
EU
LR
Legrand
FTSE
UKX
FTSE 100
NASDAQ
AAPL
Apple
NYSE
DIS
Walt Disney
EU
DG
Vinci
EU
ORA
Orange
EU
PX1
CAC 40
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés